H. Lundbeck

Alder Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies for migraine treatment. The company's lead product candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38, along with Clazakizumab, another monoclonal antibody that targets interleukin-6 and has completed two Phase 2b clinical trials. Additionally, Alder has a strategic collaboration with CSL Limited for the development of Clazakizumab as a potential treatment for solid organ transplant rejection. Founded in 2002 and headquartered in Bothell, Washington, Alder Biopharmaceuticals operates as a subsidiary of H. Lundbeck A/S, focusing on advancing innovative therapies to improve the lives of patients suffering from migraine and other conditions.

Abide Therapeutics is a clinical-stage biotechnology company focused on discovering and developing therapeutics targeting serine hydrolases, a class of enzymes that has significant potential for treating various diseases. Founded in 2011, the company operates from its headquarters in San Diego, California, and has an additional office in Princeton, New Jersey. Abide Therapeutics employs a unique platform that facilitates the efficient identification, development, and validation of small-molecule inhibitors that selectively target these enzymes. This innovative approach aims to address serious diseases with substantial unmet medical needs by enhancing the understanding of the roles serine hydrolases play in human health and disease. In 2019, Abide Therapeutics became a subsidiary of H. Lundbeck A/S, furthering its capacity for drug development.

Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural and chemistry technologies to address Parkinson’s disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson’s disease.

BenevolentAI is a clinical-stage company focused on artificial intelligence and computational medicine to transform drug discovery and development. By leveraging its proprietary platform, the company aims to enhance data-driven decision-making, ultimately lowering development costs, reducing failure rates, and accelerating the timeline for bringing new medicines to market. BenevolentAI's innovative approach has resulted in a robust pipeline of over 20 drug programs, ranging from target discovery to clinical trials. Additionally, the company engages in commercial collaborations with pharmaceutical firms, enhancing its capacity to deliver novel drug candidates that demonstrate a higher likelihood of clinical success compared to traditional methods.

Chelsea Therapeutics International, Ltd. is a development-stage pharmaceutical company based in Charlotte, North Carolina, that focuses on acquiring, developing, and commercializing treatments for various human diseases. The company is primarily engaged in developing therapeutic agents for symptomatic neurogenic orthostatic hypotension (NOH) and related conditions. Additionally, Chelsea Therapeutics is working on prescription products targeting multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and cancer. Its clinical-stage projects include droxidopa for symptomatic NOH and an array of non-metabolized antifolate compounds aimed at treating rheumatoid arthritis.

Naurex Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for depression and other central nervous system disorders. The company specializes in a new approach to modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a unique class of compounds called glycine-site functional partial agonists (GFPAs). These GFPAs interact with the NMDAR in a manner distinct from traditional agents, potentially offering new treatment options for patients. Naurex's drug development pipeline includes several programs, highlighted by the first-generation molecule GLYX-13 and the second-generation NRX-1050 series, along with additional compounds derived from its platform of novel NMDAR modulators. Through this research, Naurex aims to address the challenges posed by various CNS disorders.

Naurex Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for depression and other central nervous system disorders. The company specializes in a new approach to modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a unique class of compounds called glycine-site functional partial agonists (GFPAs). These GFPAs interact with the NMDAR in a manner distinct from traditional agents, potentially offering new treatment options for patients. Naurex's drug development pipeline includes several programs, highlighted by the first-generation molecule GLYX-13 and the second-generation NRX-1050 series, along with additional compounds derived from its platform of novel NMDAR modulators. Through this research, Naurex aims to address the challenges posed by various CNS disorders.

Proximagen is a publicly traded neuroscience research company focused on drug development for neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease.

Laboratoire Elaiapharm S.A., a pharmaceutical contract manufacturing organization, provides pharmaceutical development, manufacturing, and commercial and clinical packaging services. Its development services include feasibility studies, pre-formulation and formulation, process development and validation, galenic development, process optimization, reformulation and life cycle management, development and validation of analytical methods, ICH stabilities, and regulatory support and documentation. The company also engages in manufacturing solid dose, liquid, sterile, and non-sterile products, such as tablets, powders, hard capsules, vials, ampoules, bottles, drops, and active pharmaceutical ingredients. In addition, it offers primary and secondary packaging, clinical packaging, late stage customization, labeling, artworks management, and logistics and distribution services; and dossiers development and licensing services.

Ovation Pharmaceuticals was acquired by [Lundbeck., Inc.](/organization/lundbeck), in March 2009. The company was founded in 2000, and as of its acquisition in 2009 it operates as a subsidiary of H. Lundbeck A/S. Lundbeck, Inc., a biopharmaceutical company, engages in developing, manufacturing, and selling pharmaceutical products primarily in the United States. Its products include methamphetamine hydrochloride tablets, mephobarbital tablets, pentobarbital sodium injections, ethotoin tablets, and clorazepate dipotassium and tetrabenazine tablets. The company’s products also include antithrombin, dactinomycin, asparaginase, mechlorethamine, and hemin injections; and succimer, benztropine mesylate, indomethacin, and ibuprofen lysine injections. In addition, Lundbeck offers Sabril (vigabatrin) tablets and powder for oral solutions. Its products are used for central nervous system, hematology, and oncology-related diseases and disorders, as well as used in hospitals. The company markets its products in Argentina, Brazil, Canada, Costa Rica, Guatemala, Honduras, Mexico, Australia, Hong Kong, Korea, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, Austria, Belgium, Bulgaria, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, the United Kingdom, and Israel.

Synaptic Pharmaceutical Corporation develops human receptor-targeted drug design technology. The Company offers technology which is used to discover and clone the genes that code for human receptor subtypes that may be associated with specific disorders.